Chimeric antigen receptor T cell therapy comes to clinical practice.

Area of Science:

• Immunology
• Oncology
• Cellular Therapy

Background:

• Adoptive cellular therapy using chimeric antigen receptor T cells (CAR-T) has gained regulatory approval.
• CAR-T therapy has demonstrated significant and durable remissions in pediatric leukemia and adult non-Hodgkin lymphoma.
• This has led to a paradigm shift in treating acute lymphoblastic leukemia in children.

Purpose of the Study:

• To provide an overview of the basic concepts and treatment of CAR-T immunotherapy.
• To discuss the implications of CAR-T therapy for regulatory assessment, institutional logistics, and toxicity management.
• To share early experiences and lessons learned from implementing CAR-T therapy in a clinical setting.

Main Methods:

• Genetically modifying a patient's own T cells to express chimeric antigen receptors.
• Facilitating T cell localization to cancer cells, followed by activation, proliferation, and targeted cancer cell killing.
• Manufacturing patient-specific CAR-T products under good manufacturing standards, requiring collaboration between pharmaceutical companies and treating sites.

Main Results:

• CAR-T therapy has achieved remarkable and durable remissions in pediatric recurrent/refractory leukemia and adult non-Hodgkin lymphoma.
• The impressive responses have shifted the standard of care for pediatric acute lymphoblastic leukemia.
• Early clinical experience with both trials and commercial products has been established.

Conclusions:

• CAR-T therapy represents a novel drug class requiring new paradigms for regulatory assessment and approval.
• Institutions must address unique logistical requirements and manage novel toxicities associated with CAR-T treatments.
• Lessons learned from early implementation are crucial for advancing this new frontier in cancer therapy.